Galapagos N.V. (Euronext + Nasdaq: GLPG)

https://www.glpg.com

Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn’s disease. GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. *

	Start	1999-06-01 established_pre
	Group	Galapagos (Group)
	Predecessor	Galapagos Genomics N.V.
	Industry	genomics/genetics
	Person	Stoffels, Paul (Galapagos 202204– CEO before JnJ + Virco + Tibotec)
	Person 2	Huston, Thad (Galapagos 202307– CFO + COO before Kite + LivaNova + 25y at JnJ)

	Region	Mechelen
	Country	Belgium
	Street	Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3
	City	2800 Mechelen
	Tel	+32-15342900
		Address record changed: 2020-12-02

Basic data	Employees	F: 1,001 to 5,000 (2019-12-31)
	Currency	EUR
	Annual sales	895,890,000 (revenues + other income, total, consolidated (2019) 2019-12-31)
	Profit	149,845,000 (2019-12-31)
	Cash	5,780,832,000 (2019-12-31)

		* Document for »About Section«:

		Record changed: 2023-09-25